Relmada Therapeutics Inc. (4E2)
XDUS 
Summary
4E2 Chart
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Relmada Therapeutics Q2 Earnings Call Highlights
Relmada Therapeutics NASDAQ: RLMD said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026.
Relmada Therapeutics Inc. (4E2) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Relmada Therapeutics Inc. ever had a stock split?
Relmada Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sergio Traversa CEO | XDUS Exchange | US75955J4022 ISIN |
| US Country | 17 Employees | 30 Sep 2019 Last Dividend | 30 Sep 2019 Last Split | 9 Oct 2014 IPO Date |
Overview
Relmada Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating treatments for central nervous system (CNS) diseases and other disorders. Established in 2004 and based in Coral Gables, Florida, the company is at the forefront of researching and producing innovative therapies that address a variety of mental and neurological conditions. Their approach combines cutting-edge science with a deep understanding of patient needs to develop new therapeutic options for diseases that are currently difficult to treat.
Products and Services
- Esmethadone (d-methadone, dextromethadone, and REL-1017): This lead product candidate represents a major innovation in the treatment of central nervous system disorders. As a new chemical entity, Esmethadone acts as an N-methyl-D-aspartate receptor antagonist. Currently, it is under Phase 3 clinical trials specifically designed to evaluate its efficacy as an adjunctive or monotherapy in the treatment of major depressive disorder in adults. This focus on a key area of unmet medical need, major depressive disorder, highlights Relmada Therapeutics' commitment to addressing the challenges within the realm of mental health treatment through advanced scientific research.
